

SMARTHEAT INC.  
Form 10-Q  
May 09, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2008

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53052

SMARTHEAT INC.  
(Exact name of registrant as specified in its charter)

NEVADA  
(State or other jurisdiction of  
incorporation or organization)

98-0514768  
(IRS Employer  
Identification No.)

A-1, 10, Street 7  
Shenyang Economic and Technological Development Zone  
Shenyang, China  
110027  
(Address of principal executive offices, including zip code.)

+86 (24) 2519-7699  
(telephone number, including area code)

(Former name or former address, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.

YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company

(do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
YES [ ] NO [ X ]

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 22,549,000 shares as of April 30, 2008.

---

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Balance Sheets	F-1
Statements of Operations	F-2
Statements of Cash Flows	F-3
Note to Financial Statements	F-4

---

SmartHeat Inc.  
(formerly Pacific Goldrim Resources, Inc.)  
(An Exploration Stage Company)

Balance Sheets

	March 31, 2008 (Unaudited) \$	October 31, 2007 (Audited) \$
Assets		
Current Assets		
Cash	7,338	9,185
Accounts receivable	772	-
	8,110	9,185
Liabilities and Stockholders' Deficiency		
Current Liabilities		
Accounts payable	16,429	250
Stockholders' Deficiency		
Common Stock		
75,000,000 shares authorized, with a \$0.001 par value, 6,549,900 shares issued and outstanding	6,549	6,549
Additional Paid-in Capital	38,426	38,426
Deficit Accumulated During the Exploration Stage	(53,294)	(36,040)
Total Stockholders' Deficiency	(8,319)	8,935
Total Liabilities and Stockholders' Deficiency	8,110	9,185

The accompanying notes are an integral part of these financial statements



SmartHeat Inc.  
(formerly Pacific Goldrim Resources, Inc.)  
(An Exploration Stage Company)

Statements of Operations  
(Unaudited)

	Two Months Ended March, 31		Five Months Ended March, 31		August 4, 2006 (date of inception) to March 31,
	2008	2007	2008	2007	2008
	\$	\$	\$	\$	\$
Expenses					
Accounting and administration	400			450	
Audit fees	10,778	100	1,000		2,800
Bank charges	23	–	10,778	3,000	24,617
General office expense	107	16	68	113	325
Legal fees	1,802	170	260	310	843
Legal fees	1,802	–	1,802	8,186	11,988
Mineral property costs	–	–	–	–	6,694
Transfer agent and filing fees	2,570	50	3,346	901	6,027
Total Expenses	15,680	336	17,254	12,960	53,294
Net Loss	(15,680)	(336)	(17,254)	(12,960)	(53,294)
Basic and Diluted Net Loss Per Share	(0.00)	(0.00)	(0.00)	(0.00)	
Weighted Average Number of Shares Outstanding – basic and diluted	6,549,900	6,549,900	6,549,900	6,549,900	

The accompanying notes are an integral part of these financial statements



SmartHeat Inc.  
 (formerly Pacific Goldrim Resources, Inc.)  
 (An Exploration Stage Company)

Statements of Cash Flows  
 (Unaudited)

Five Months Ended	August 4, 2006
March 31,	(date of inception)
2008	to March 31,
\$	2008
	assays
	Transfection
	Rolling Circle
	Amplification
	RCAT
	Signal
	amplification
	Luminex
	Assay acceleration
	chemistries
	etc.
	General and
	Supporting
	Technologies
	Instrumentation
	Software
	Plastic
	Manufacturing
	technologies
	Packaging
	technologies
	Microfluidic
	technologies
	etc.
	IP (12/05): 409
	issued, 321 pending
	patents >500 under
	license
	license
	QIAGEN
	Technology and
	Innovation
	Sample
	Assay
	Technologies







Sample & Assay Technologies

-

17

-

QIAGEN/Digene

Creating a Leader in MDx

Disseminating Technologies Into Four Markets

Product and Technology Continuum

Academia

Life Science

Research

Applied

Testing

Molecular

Diagnostics

Pharma  
Research &  
Development  
Sample  
Assay  
SAMPLE  
Technologies  
ASSAY  
Techologies

Sample & Assay Technologies

-

18

-

QIAGEN/Digene

Creating a Leader in MDx

Bringing

Full Power To Our  
Customers  
Globally aligned Sales and Marketing  
Customer focused  
scaleable  
critical mass  
One core = multiple channels  
We  
are  
Life Sciences  
Sales  
Pharma  
Key Account  
Manager  
Applied  
Testing  
Sales  
Developer  
MDx  
Sales  
SAMPLE  
TECHNOLOGIES  
ASSAY  
TECHNOLOGIES  
Diagnostic  
Pharma  
Biotech  
Academia  
Veterinary  
Forensics  
Food  
Diagnostics  
Sales  
Specialists  
AT  
Sales  
Developers  
Pharma  
KAMs  
Life  
Sciences  
Sales  
Life Sciences  
Marketing  
Manager  
Pharma  
Marketing  
Manager  
Applied Testing  
Marketing

Manager  
Diagnostic  
Marketing  
Manager  
Customer  
Sales  
force  
Marketing  
force  
Sample  
Assay

Sample & Assay Technologies

-

19

-

QIAGEN/Digene

Creating a Leader in MDx

MDx



And Applied  
Testing  
Account  
For 35%  
Revenue  
breakdown  
for  
segments  
Focus provides strength -  
new markets drive growth

.  
Focused core competency:  
Sample and assay technologies

.  
Four Markets:  
Life Sciences Academia  
Pharma Research & Development  
Applied Testing  
Forensics  
Veterinary  
Other  
Molecular Diagnostics  
SAMPLE  
TECHNOLOGIES  
ASSAY  
TECHNOLOGIES  
Sample  
Assay



Sample & Assay Technologies

-  
20

-  
QIAGEN/Digene  
Creating a Leader in MDx  
Creating a Global Leader in Molecular Diagnostics  
Who  
is  
QIAGEN?  
What  
is  
our  
strategy?  
What  
do we  
do in Diagnostics ?

Sample & Assay Technologies

-

21

-

QIAGEN/Digene

Creating a Leader in MDx

Molecular Diagnostics Growth Strategy

Multiple, Synergistic Channels  
Focused Direct Sales Resources

Direct sales  
OEM development  
OEM sales

.

Direct Sales  
Growing direct sales force > 150 -  
160

(1)  
Focus on pathogens  
Market leader in developing countries  
China  
strong #2

.

OEM Products  
Integrated solutions, CE and FDA  
Assays, preanalytical, automation  
> 15 Partners  
Developing solutions for partners  
(1) NA 23, EU 28, Rest Asia  
Sample  
Assay  
MDx

Sample & Assay Technologies

-

22

-

QIAGEN/Digene

Creating a Leader in MDx

QIAGEN Has Developed More Than 30 PCR Assays

Cytomegalovirus  
Dengue virus  
Epstein-Barr virus  
Enterovirus  
Hepatitis A virus  
Hepatitis B virus  
Human immunodeficiency  
virus-1  
Herpes  
simplex virus  
Influenzavirus  
Influenzavirus  
H5 (Avian flu)  
Orthopoxvirus  
Parvovirus B19  
SARS-Coronavirus  
Varicella  
Zoster virus  
West Nile virus  
Bacillus anthracis  
Borrelia  
spec.  
Campylobacter spec  
Chlamydia trachomatis  
Listeria  
monocytogenes  
Mycobacterium paratuberculosis  
Mycobacterium tub. diff.  
Mycobacterium  
Mycoplasma  
pneumoniae  
Salmonella spec.  
Viruses  
Bacteria  
Parasites  
Pharmacogenetics  
DPD PCR kit  
MTHFR PCR kit  
TPMT PCR kit  
Plasmodium spec  
Representative but not complete list  
Strength:  
Sensitivity  
and  
Specificity  
Sample  
Assay  
MDx







Sample & Assay Technologies

QIAGEN

Digene: Creating a Leader in MDx, June 4, 2007

-

23

-

QIAplex: Novel and Innovative Multiplex Technology

Sample

Assay

MDx

Syndrome

Patient

Presentation

Selected

qPCR

Test

Confirmed

Pathogen ID

Potential

Pathogens

hMPV

hMPV

Selection

of test for

one potential

pathogen

QIAplex

Panel

SARS

Avian

Flu

RSVA

RSVB  
hMPV  
PIVI  
PIVII  
Ent  
Rhino  
Coxsac  
kie  
SARS  
Avian Flu  
RSVA  
RSVB  
hMPV  
PIVI  
PIVII  
Ent  
Rhino  
Coxsackie  
Multiplexing:  
Screening Technology  
qPCR:  
High resolution confirmation/quantification

Sample & Assay Technologies

-

24

-

QIAGEN/Digene

Creating a Leader in MDx

Tangible Opportunities for Future Growth Synergies

Significant Growth Synergies

Exciting near-term product synergies:

Multiplexing technologies for future genotyping application

Sample preparation

Next-generation assay technologies

Assay breadth in woman's health

Exciting other synergies include:

QIAGEN is key supplier to vaccine developers

Manufacturing capacity

Channel lends itself to many future assay opportunities

Fast**HPV**

platform in developing countries,

QIAGEN has channel

Next generation instrumentation

And many more to come

Sample & Assay Technologies

-

25

-

QIAGEN/Digene

Creating a Leader in MDx

QIAGEN and Digene

15 year partnership in Molecular Diagnostics  
>15 year partnership between QIAGEN and Digene  
Digene products leverage QIAGEN sample and  
assay technologies  
Example: RapidCapture  
system  
Core platform of Digene  
FDA approved solution, used in HPV testing  
Digene sole marketer  
Next generation platform development programs  
Partnership  
Similar cultures  
Focus -  
Excellence

Sample & Assay Technologies

-

26

-

QIAGEN/Digene

Creating a Leader in MDx

QIAGEN and Digene -



Direct Neighbors  
Germantown and Gaithersburg MD  
Companies are 5 minutes apart (2.8 miles)



Sample & Assay Technologies

-

27

-

QIAGEN/Digene

Creating a Leader in MDx

The Combination Creates Real Value

For All

Market and technology leader in molecular diagnostics\*)

over \$350 million of molecular diagnostics revenue

Targeting > \$800 million in total revenues in 2008

Unique technology and product portfolio

Fastest growing product portfolio; Most complete technology portfolio

Absolute leader in key >\$1 billion HPV segment

Most powerful sales and marketing channel to realize technology potential

Over 300 professionals in MDx marketing and sales

Over 1000 overall sales and marketing professionals

Excellent basis for future expansion and growth

Truly global sales and marketing presence

Leading technologies and R&D

World class capabilities and organization to ensure success

Compelling financial profile and value creation opportunity

Enhanced growth profile and combined profitability

QIAGEN's Breadth and Platforms + Digene's

Content

\*) Ex blood banks and viral load

VAL

UE

Sample & Assay Technologies

-

28

-

QIAGEN/Digene

Creating a Leader in MDx

The Combination Accelerates

QIAGEN's Molecular Strategy

Digene's

highly

focused

strategy

in

MDx

is

a

unique

fit

with

QIAGEN

QIAGEN's strategy: leadership in Sample & Assay Technologies

in research, pharma, applied testing and MDx

Same target customers in MDx

Superb brands and reputations

HPV

testing

is

fastest

growing,

large

segment

in

MDx

with

over

\$1

billion

market potential

Digene's

strong IP positions in HPV

over 70 subtypes

HPV bridges QIAGEN's virology leadership into emerging,

fast growing oncology segment

Important HPV assay creates unique value for QIAGEN's

platforms and assay breadth

.

Leading regulatory expertise

only FDA approved test for HPV

Great fit with QIAGEN's emerging pipeline

.

Enhanced growth profile and combined profitability leads to

strong value creation

QIAGEN's Breadth and Platforms + Digene's

Content

Sample & Assay Technologies

-

29

-

QIAGEN/Digene

Creating a Leader in MDx

The Combination Accelerates

Digene's

Development Goals

QIAGEN's unparalleled sample and assay technology breadth creates opportunities for future:

Adds key assay technologies such as multiplexing (QIAplex), PCR, isothermal technologies

Adds key sample technologies such as DNA processing from cervical swabs

QIAGEN's broad assay portfolio offers new value for Digene's customers and

Next generation platform programs

QIAGEN's global sales strength accelerates rapid and global rollout

Digene can take advantage of QIAGEN's operations and infrastructure which are needed for next phase of growth

QIAGEN's Breadth and Platforms + Digene's

Content

Sample & Assay Technologies

-

30

-

QIAGEN/Digene

Creating a Leader in MDx

World-Class Capabilities & Organization Ensure Success



Great breadth and depth of management team  
Strong leaders from both companies  
Leading expertise in molecular diagnostics and life sciences  
Strong foundation for collaboration built upon 15-year partnership  
Similar cultures and strong working relationship  
Strong synergies  
growth allows retention of talent base  
Integration plan well-developed  
12 month process, clear timelines  
Mirrored teams  
Being neighbors a big advantage  
Maryland: headquarters of MDx business  
QIAGEN has proven track record in very successfully integrating  
12 companies in last 3 years.  
We are  
Huge Growth Potential -  
Increasing Awareness





Sample & Assay Technologies

-  
31

-  
For Internal Use Only

Four Phases to an effective Integration of Digene

Phase 0

Pre-Process

planning

Phase 2

Detailed planning &  
decision making

Phase 3

Implementation &  
execution

Phase 1

Issue identification  
and action planning

Appoint and launch  
integration teams

Communicate

Stabilize the business

Establish resource  
baselines for both  
companies

Identify key integration  
issues and areas for  
synergy realization

Communication

Identify integration  
opportunities

Develop/decide on future  
business structure  
Validate plans in detail  
Initiate execution of short  
term actions  
Return first units to  
business-as-usual  
Finalize Budget 2008  
Communicate  
Resolve open issues  
Implementing decisions  
Monitor target achievement  
Manage as single company  
Communicate  
Define integration process  
and timeline  
Define integration approach  
& responsibilities  
Plan, plan, plan  
Agree on integration  
resources, project teams,  
charter & external support  
Develop organizational and  
core operating model  
Determine targets  
Communication  
Pre-closing  
Plan  
Budget 2008  
"Achievements"  
Pre-announcement/  
Pre-closing  
Day of public  
announcement  
Ca. September 2007  
December  
2007  
June  
2008

Sample & Assay Technologies

-

32

-

QIAGEN/Digene

Creating a Leader in MDx

Integration should be accomplished in 6

12 months

10

20

30

40

50

10

20

30

40

50

Load dependent

on requirements

Handover

Resources

FTE

Integration

Accomplished

Line function

Take over responsibilities

Jul

Jun

May

Mar

Apr

Jan

Feb

May

Jun

Jul

Oct

Nov

Aug

Sep

Dec

Aug

Sep

Apr

Line function responsible

Integration Project

Functional project

In transition

Announcement

3. June

Closing

Announce-

ment

Pre-

Planing

Closing

New  
Budget 2008  
Pre-  
Closing  
Post-  
Closing  
Implementation



Sample & Assay Technologies

-

33

-

QIAGEN/Digene  
Creating a Leader in MDx  
Project Structure

for  
Integration  
Special Projects  
Functional Projects  
Business Projects  
Responsible for the bulk of  
the integration  
Made up from representatives  
of the different functions of  
both companies  
Develop guide-lines to ensure  
consistency around the world  
Responsible for planning and  
tracking the overall process  
Help to identify and resolve  
emerging issues  
Responsible for leading the  
integration process  
Divestments  
&  
Acquisition  
New mission  
&  
Steering  
principles  
Locations  
/ Property  
Brand management  
HR  
IT  
Manufacturing  
R&D  
Regulatory  
Administration  
Marketing Asia  
Marketing Europe  
Marketing USA,  
Americas  
Global Product  
Management  
Distributor  
Sales Europe  
Sales Asia  
Sales USA,  
Americas  
Integration office  
Communication  
.  
Doug  
Liu

Joe  
Slattery  
Doug White      Thomas Schweins  
Project Team  
Steering  
Committee  
Peer Schatz      Daryl Faulkner

Sample & Assay Technologies

-

34

-

QIAGEN/Digene

Creating a Leader in MDx

Doug Liu

VP Global Operations

QIAGEN

Douglas Liu

VP Global Operations

Doug Liu joined

QIAGEN in 2005

MBA from

Boston University

Science degree

from

the

University of Illinois

Multifunctional

background

in diagnostic

Industry

Operations

Strategic

planning

and

R&D

.

20 years

track

record

of success

in Molecular diagnostics

Bayer Operation Head

-

Nucleic

Acid

Diagnostics

Bayer Strategic

Planning and Consulting

Abbott Diagnostics

Chiron

Diagnostics

Sample & Assay Technologies

-

35

-

QIAGEN/Digene

Creating a Leader in MDx

Doug White

SVP Sales & Marketing  
Digene  
Douglas White  
SVP Sales & Marketing  
Americas  
and Asia Pacific

.  
Doug White joined  
Digene in 2003  
Started  
as VP Sales & Marketing North America  
Oversees  
commercial  
operations  
incl. Sales,  
Marketing Service and Support  
Americas  
and Asia Pacific

.  
20 years  
of sales  
& marketing  
experience  
in health  
care

.  
10 years  
track  
record  
of success  
in Molecular diagnostics  
SVP Global Marketing at Roche Molecular Systems  
VP Sales & Marketing at Bayer  
Vice  
President  
of US Marketing at Chiron  
Abbott Diagnostics

Sample & Assay Technologies

-

36

-

QIAGEN/Digene

Creating a Leader in MDx

Joseph



P.  
Slattery  
Chief  
Financial Officer  
and  
Senior Vice  
President

.  
Joe Slattery joined  
Digene in 1996  
Corporation s  
finance, accounting,  
investor  
relations, treasury, information  
systems  
program  
management  
operations  
Mr. Slattery was appointed  
Chief  
Financial Officer  
Oct  
2006.

.  
Prior to Digene, Joe worked  
in public  
accounting  
KPMG  
Peat  
Marwick  
Ernst & Young LLP

.  
He received  
a B.S. in accounting  
from  
Bentley College  
and is  
a certified  
public  
accountant.  
Joe Slattery  
Chief  
Financial Officer  
Digene

Sample & Assay Technologies

-

37

-

QIAGEN/Digene  
Creating a Leader in MDx  
Thomas Schweins

VP Marketing & Strategy  
Thomas Schweins  
VP Marketing & Strategy  
QIAGEN

.  
Thomas Schweins joined  
QIAGEN in 2004  
Biochemistry, University Hannover  
Business Administration, USC Los Angeles  
PhD, Max Planck Institute, Heidelberg

.  
Multifunctional  
background  
in Life Science Industry  
Strategy  
and Strategic  
Planning  
Marketing  
R&D  
Post-Merger-Integration

.  
15 years  
track  
record  
of success  
in Life Sciences  
Senior Manager Boston Consulting  
Group  
Senior Project Manager Aventis  
Technology & Business Dev  
Manager Hoechst

Sample & Assay Technologies

QIAGEN

Digene: Creating a Leader in MDx, June 4, 2007

-

38

-

Questions and Answers

If  
you  
have  
further  
questions:  
Call  
+240-686 7362  
E-mail  
Merger@qiagen.com

Disclaimer Regarding Forward-Looking Statements

Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of QIAGEN's products, the timing of the completion of the transaction between QIAGEN and Digene, the anticipated benefits of the business combination transaction involving QIAGEN and Digene, including future financial and operating results, the expected financing for the transaction, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. QIAGEN and Digene caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties may be unable to complete the transaction because conditions to the closing of the transaction may not be satisfied; the risk that the businesses will not be integrated successfully; the transaction may involve unexpected costs or unexpected liabilities; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. In addition, the transaction will require the combined company to obtain significant financing. The combined company's liquidity and results of operations could be materially adversely affected if such financing is not available on favorable terms.

Moreover, the substantial leverage resulting from such financing will subject the combined company's business to additional risks and uncertainties. The risks included above are not exhaustive. The most recent reports on Form 20-F, Form 6-K and other periodic reports filed with or furnished to the Securities and Exchange Commission by QIAGEN and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Digene with the Securities and Exchange Commission contain additional factors that could impact the combined company's businesses and financial performance. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information

QIAGEN is filing today a Current Report on Form 6-K that will include as exhibits the Agreement and Plan of Merger among QIAGEN, QIAGEN North American Holdings, Inc., QIAGEN's merger subsidiary and Digene Corporation. QIAGEN intends to file a Registration Statement on Form F-4 and a Schedule TO, and Digene plans to file a Solicitation/Recommendation Statement on Schedule 14D-9, with the Securities and Exchange Commission in connection with the transaction. QIAGEN and Digene expect to mail a Prospectus, which is part of the Registration Statement on Form F-4, the Solicitation/Recommendation Statement on Schedule 14D-9 and related exchange offer materials, including a letter of election and transmittal, to shareholders of Digene upon commencement of the exchange offer. These documents contain important information about the transaction and should be read before any decision is made with respect to the exchange offer. Investors and stockholders will be able to obtain free copies of these documents through the website maintained by the Securities and Exchange Commission at [www.sec.gov](http://www.sec.gov). Free copies of these documents may also be obtained from QIAGEN, by directing a request to QIAGEN's IR department at QIAGEN Strasse 1, 40724 Hilden, Germany, or from Digene, by directing a request to Digene at 1201 Clopper Road, Gaithersburg, MD, 20878.

In addition to the Registration Statement on Form F-4, Schedule TO, Prospectus, Solicitation/Recommendation Statement on Schedule 14D-9 and related exchange offer materials, both QIAGEN and Digene file or furnish annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy any reports, statements or other information filed or furnished by QIAGEN or Digene at the SEC's Public Reference Room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. QIAGEN's and Digene's SEC filings are also available to the public at the SEC's web site at <http://www.sec.gov>, or at their web sites at [www.qiagen.com](http://www.qiagen.com) or [www.digene.com](http://www.digene.com).